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Sixty-four severe infections in hospitalized patients were treated with intravenous
Timentin. Most patients (mean age: 50-5 years, range 18-85) had serious underlying
conditions such as agranulocytosis, heart failure, cancer, diabetes mellitus, chronic
alcoholism or other functional or anatomical abnormalities. Forty-three episodes
were bacteriologjcally proved, and bacteraemia was diagnosed in 18. The sites of
infection were: lower respiratory tract (10), upper respiratory tract (10), soft tissues
(9), urinary tract (7), bones (6), peritoneal cavity (3), meninges (1) and pelvis (1). In
addition, 13 episodes of fever and four of septicaemia in patients with
agranulocytosis were treated with Timentin plus amilcacin. Overall, 59% of the
episodes were cured, 14% improved and 17% failed to respond. In 9% of cases the
efficacy of the Timentin was unassessable mainly because of concurrent
administration of other antimicrobials. Failure appeared to be more frequent in soft
tissue and intra-abdominal infections, in patients infected with bacteria susceptible
to Timentin but resistant to ticarcillin and in patients superinfected with Timentin-
resistant strains. Major side effects were haemorrhagic diathesis with platelet
dysfunction (1), severe water sodium overload (1), and possibly pancreatitis (1).
Other side effects were mild: catheter-related phlebitis, and abnormal but clinically
insignificant laboratory test results. Timentin appears to be an effective and safe
broad-spectrum combination which compares favourably with third-generation
cephalosporins in the treatment of severe hospital infections. More experience is
needed to decide whether the somewhat lower response rate in patients infected with
ticarcillin-resistant strains is significant
Introduction
Clavulanic acid, a potent inhibitor of bacterial /f-lactamases, prevents destruction of
penicillins by /Mactamase-producing organisms (Hunter et al., 1980; Neu & Fu, 1978).
The addition of clavulanic acid extends the spectrum of ticarcillin to include /?-
lactamase-producing strains of Staphylococcus aureus, Enterobacteriaceae, Gram-
negative anaerobic rods, Haemophilus influenzae and some strains of Pseudomonas
aeruginosa (Casey & Glauser, 1983; Lamothe, Auger & Lacroix, 1984; Fuchs et al.,
1984; Barry et al., 1984; Clarke & Zemcov, 1984; Hunter et al., 1980). The availability
of an intravenous formulation of ticarcillin plus clavulanic acid (Timentin) prompted
its clinical trial in the treatment of severe hospital infections.
Materials and methods
In-patients at the Centre Hospitalier Universitaire Vaudois, Lausanne, who required
broad-spectrum antibiotic therapy for severe infections were eligible for inclusion in the
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study. Patients excluded were those with penicillin hypersensitivity, pregnant women,
and patients who had received antimicrobials within the previous 72 h, unless those
antimicrobials had proved ineffective.
Timentin was administered intravenously. Patients with normal renal function
received 3-2 g (3 g ticarcillin+0-2 g clavulanic acid) 4-hourly (7 patients) or 6-hourly
(28 patients), or 5-2 g (5 g ticarcillin + 0-2 g clavulanic acid) 6-hourly (22 patients). The
patients with renal failure received 3-2 g bd, 1-6 g (1-5 g ticarcillin + 0-1 g clavulanic
acid) bd, 5-2 g bd, or 2-6 g (2-5 g ticarcillin+01 g clavulanic acid) tds (one patient each
dosage). The duration of treatment varied from 2-45 days (mean 12-5 days). Six
patients were treated for less than five days either because a side effect (one case) or
primary bacterial resistance (five cases) prompted a change of antimicrobial.
Samples of blood and appropriate specimens were collected for culture and
susceptibility testing within two days before, and two to five days after commencement
of therapy as well as two or three days and one or two weeks after the end of therapy
(four weeks for urinary tract infections). Organisms were considered pathogenic if they
grew from an appropriate specimen in an appropriate number and if the clinical setting
was consistent. Disc diffusion susceptibility testing was performed as proposed by
Fuchs et al. (1984).
Blood and urine specimens were drawn for haematological and biochemical
investigations before the start of therapy, then at five-day intervals and at the end of
therapy. Granulocytopenia was defined as less than 100 neutrophils per /J of blood.
Classification of responses to treatment
Clinical response. Patients were considered as clinically cured when clinical
abnormalities subsided with no evidence of infection when the drug was discontinued
or during follow-up; as improved when clinical abnormalities definitely diminished but
with incomplete resolution of infection. Clinical failure was defined as no (or only
transient) response to therapy. Patients were thought unassessable when they received
concurrent appropriate antibiotherapy (with the exception of leukopenic patients
receiving Timentin plus amikacin), or when Timentin was replaced at an early stage by
other antimicrobials because of either Timentin resistance of the primary pathogen, or
because of serious Timentin side effects.
The bacteriological response was classified as follows: eradication when the cultures
from the original site of infection became negative; cure when clinical improvement was
such that culture material was no longer available; failure when one or more culture
sites remained positive for the same organism; relapse when, after becoming initially
negative, cultures again grew the same organism; and reinfection when cultures showed
secondary growth of another organism.
Results
Sixty-four episodes were studied in 62 patients. There were 41 males and 21 females,
aged from 18 to 85 years (mean 50-5). A large number of associated conditions were
present, as shown in Tables II to Vm.
Patient data are detailed in Tables II to VIII and summarized in Table IX. Overall,
clinical cure or improvement were achieved in 59% and 14% respectively of the
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Table I. Results of susceptibility testing of Timentin and ticarcillin'
No. of isolates susceptible to:
No. of Timentin and Timentin but Neither Timentin
Organisms isolates ticarcillin not ticarcillin nor ticarcillin
E.coli 13 10 3
P. aeruginosa 13 10 1 2
KlebsieUa spp. 5 4 1
Proteus spp. 5 5
Morganella morganii 5 4 1
Other Gram-negative rods* 4 2 2
5. aweus 7 2 5
Other Gram-positive coccic 9 9
Anaerobic bacteria' 9 8 1
Totals 70 50 15 5
"Performed by agar diffusion, or broth dilution for anaerobic isolates.
bC.freundii (1), Ent. cloacae (1), P. cepacia (1), Aeromonas hydrophila (1).
'S. epidermidis (1), Group D, streptococci (5), Str. milleri (2), Group A streptococcus (1).
'Bacteroides fragilis (1), B. naninicola (1), B. melaninogeniau (2), B. oralis (1), B. thelaiotaomicron (1),
Peptococcus species (2), Eubacterium lentum (1).
episodes. Thus, response to treatment occurred in 73% of the cases. There were 11
failures, while outcome could not be assessed in six cases.
Twenty-one episodes were not bacteriologically proved (of which 13 were fever in
leukopenic patients). Among the 43 proved episodes, 25 were thought to be caused by
one isolate, nine by two isolates and nine by three isolates. Thus 70 isolates were tested
for ticarcillin and Timentin susceptibility (Table I). In five cases infection was caused
by a pathogen found to be resistant to Timentin before Timentin administration. In
five further cases a Timentin-resistant isolate appeared during treatment. Two patients
had a reinfection with Timentin-resistant Escherichia coli and Klebsiella pneumoniae,
and this resulted in failure. In three patients Timentin-resistant Citrobacter freundii,
Enterobacter cloacae and P. aeruginosa respectively appeared after a corresponding
Timentin-susceptible strain had been cultivated before treatment. This resulted in
failure in two patients, while one patient was cured with concurrent gentamicin therapy
to which the organism was susceptible. Of the 26 episodes caused exclusively by
isolates susceptible to both Timentin and ticarcillin, 18 (69%) responded, five failed
and two were unassessable. In contrast, of the 11 episodes caused by at least one strain
susceptible to Timentin but resistant to ticarcillin, five (45%) responded, four failed and
two were unassessable.
Adverse events
Three patients had side-effects severe enough to stop Timentin therapy. In one patient
severe haematuria was accompanied by a prolonged bleeding time and impairment of
ADP-induced platelet aggregation. Another patient developed pancreatitis without
having any of the risk factors known to be associated with this condition. In both
patients the problems resolved after Timentin withdrawal. One cirrhotic patient had a
marked weight increase attributed to sodium overload secondary to Timentin
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catheter related phlebitis (10), minor changes in liver function tests (4), eosinophilia
(2), and thrombocytopenia (1). A positive direct Coombs test developed in seven of 25
patients tested but there was no evidence of haemolysis. Skin rash and diarrhoea were
not observed.
Discussion
This study demonstrates the clinical efficacy of Timentin against severe infections
occurring in debilitated patients and due to a wide range of pathogens. However, the
response rate (73%) is lower than that found in other clinical trials of Timentin (File et
al., 1984; Roselle et al., 1985). In our study, failure mainly occurred in abdominal and
soft tissue infections in patients with severe underlying conditions which clearly
represented a difficult challenge to antibiotic therapy. Other authors have observed
apparently discrepant response rates with other antibiotics such as ceftazidime
(Francioli et al., 1983; Hoogkamp-Korstanje, van Erpecum & van Kamp, 1985), and
ascribed them to differences in the numbers of patients with serious underlying
conditions (Hoogkamp-Korstanje et al. 1985).
The appearance of Timentin-resistant isolates may explain some of our treatment
failures. In five instances a resistant pathogen appeared during therapy, resulting in
four failures; one case was unassessable because of concurrent therapy. In five instances
infection was caused by a pathogen found to be resistant to Timentin before Timentin
administration. This incidence of Timentin resistance among primary pathogens
contrasts with previous findings at our institution. Among 404 blood cultures isolated
between 1979 and 1981, only five P. aeruginosa were found not to be inhibited by
32 mg/1 ticarcillin in the presence of 5 mg/1 clavulanic acid (Casey & Glauser, 1983).
Although our study population was selected for severe disease caused by multiresistant
organisms, these figures may suggest that Timentin resistance is becoming more
common in our hospital and it can now be observed in species other than
P. aeruginosa. The frequent occurrence of mixed infections precluded an analysis of the
efficacy of Timentin with respect to the infecting species. However, our data indicate
that clavulanic acid did not restore ticarcillin activity against most ticarcillin-resistant
P. aeruginosa, thus confirming previous reports (Casey & Glauser, 1983; Fuchs et al.,
1984; Barry et al., 1984).
The somewhat lower response rate in patients infected with ticarcillin-resistant but
Timentin-susceptible strains, when compared to patients infected by strains susceptible
to both antibiotics, is conspicuous but difficult to interpret because the two groups were
not comparable, making the significance of the difference questionable.
Timentin was generally well tolerated. Two patients had severe adverse events which
could be explained solely on the basis of the known properties of ticarcillin, i.e. a
ticarcillin-induced platelet function impairment (Bang & Kammer, 1983), and a water-
sodium overload. In one case there was a questionable relationship between Timentin
therapy and the development of pancreatitis. In no other instances did an adverse
event make discontinuation of Timentin necessary. The high proportion of positive
Coombs tests was not unexpected, having been reported by Williams et al. (1985). It is
caused by clavulanic acid-mediated non-immune adsorption of plasma proteins on the
erythrocyte surface, a phenomenon unassociated with haemolysis.
In summary, Timentin proved to be a safe and effective broad-spectrum agent for
the treatment of severe hospital infections. However, development of resistance during
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therapy or reinfection with resistant organisms are a matter of concern, and the need to
add an aminoglycoside to Timentin in these settings should be explored.
Acknowledgements
We thank Beecham AG, Bern, for providing Timentin; Dr P. Francioli, B. Yersin and
Dr J. Bille and Dr M. Heitz.
References
Bang, N. U. & Kammer, R. B. (1983). Hematologic complications associated with /Mactam
antibiotics. Reviews of Infectious Diseases, Suppl. 2, S380-93.
Barry, A. L., Aycrs, L. W., Gavan, T. L., Gerlach, E. H. & Jones, R. N. (1984). In vitro activity
of ticarcillin plus clavulanic acid against bacteria isolated in three centers. European Journal
of Clinical Microbiology 3, 203—6.
Casey, P. & Glauser, M. (1983). Susceptibility of Gram-negative bacteria and Staphylococcus
aureus to combinations of ticarcillin and clavulanic acid. European Journal of Clinical
Microbiology 2, 541-7.
Clarke, A. M. & Zerncov, S. J. V. (1984). Clavulanic acid in combination with ticarcillin: an in-
vitro comparison with other /Mactams. Journal of Antimicrobial Chemotherapy 13, 121-8.
File, T. M., Tan, J. S., Salstrom, S.-J., Johnson, L. A. & Douglas, G. F. (1984). Timentin versus
piperacillin or moxalactam in the therapy of acute bacterial infections. Antimicrobial Agents
and Chemotherapy 26, 310-3.
Francioli, P., Clement, M., Geroulanos, S., von Graevenitz, A., Luthy, R., Regamey, C ,
Stalder, H., Vogt, M. & Waldvogel, F. A. (1983). Ceftazidime in severe infections: a Swiss
multicentrc study. Journal of Antimicrobial Chemotherapy 12, Suppl. A. 139-46.
Fuchs, P. C , Barry, A. L., Thornsberry, C. & Jones, R. N. (1984). In vitro activity of ticarcillin
plus clavulanic acid against 632 clinical isolates. Antimicrobial Agents and Chemotherapy 25,
Fuchs, P. C , Jones, R. N., Barry, A. L. & Thornsberry, C. (1984). Disk diffusion susceptibility
testing of ticarcillin plus clavulanic acid. Journal of Clinical Microbiology 19, 555-7.
Hoogkamp-Korstanje, J. A. A., van Erpecum, K.. J. & van Kamp, H. (1985). Ceftazidime in
serious hospital-acquired infections. Journal of Antimicrobial Chemotherapy 15, 743-9.
Hunter, P. A., Coleman, K., Fisher, J. & Taylor, D. (1980). In vitro synergistic properties of
clavulanic acid, with ampicillin, amoxycillin and ticarcillin. Journal of Antimicrobial
Chemotherapy 6, 455-70.
Lamothe, F., Auger, F. & Lacroix, J.-M. (1984). Effect of clavulanic acid on the activities of ten
/Mactam agents against members of the Bacteroides fragilis group. Antimicrobial Agents and
Chemotherapy 25, 662-5.
Neu, H. C. & Fu, K. P. (1978). Clavulanic acid, a novel inhibitor of /Mactamases. Antimicrobial
Agents and Chemotherapy 14, 650-5.
Roselle, G. A., Bode, R., Hamilton, B., Bibler, M., Sullivan, R., Douce, R., Staneck, J. L. &
Bullock, W. E. (1985). Clinical trial of the efficacy and safety of ticarcillin and clavulanic
acid. Antimicrobial Agents and Chemotherapy 27, 291-6.
Williams, M. E., Thomas, D., Harman, C. P., Mintz, P. D. & Donowith, G. R. (1985). Positive
direct antiglobulin tests due to clavulanic acid. Antimicrobial Agents and Chemotherapy 27,
125-7.
